Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Seth Klarman’s Baupost Group Holdings...
Paratek Pharmaceuticals, Inc. (PRTK) Q3 2019 Earnings Conference Call November 12, 2019 04:30 PM ET Company Participants Ben Strain - Vice President of Investor Relations and Corporate Communications Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial...
Paratek Pharmaceuticals (NASDAQ: PRTK ): Q3 GAAP EPS of -$1.00 beats by $0.05 . Revenue of $3.93M misses by $0.21M . Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- Third Quarter 2019 NUZYRA ® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated -- BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage bio...
November 6, 2019 Palm Beach, FL – November 6, 2019 – Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic fact...
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcas...
Paratek Pharmaceuticals (NASDAQ: PRTK ) is off 3.7% postmarket after its top-line results from an omadacycline study suggests more studies are needed . More news on: Paratek Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating ...
Paratek Pharmaceuticals (NASDAQ: PRTK ) is up 5.5% postmarket after it announced it's withdrawn its application to the European Medicines Agency for marketing authorization for Nuzyra (omadacycline). More news on: Paratek Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...
Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studies EMA requesting second study in CABP to meet regulatory standards of two Phase 3 studies Company plans to re-submit application to EMA following completion of the planned Post-Mar...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...